Working in partnership with the AAC and NICE
There are a range of medicines that people with elevated blood cholesterol can take to help reduce the risk of cardiovascular disease (CVD). We are working in partnership with the Accelerated Access Collaborative (AAC) and the National Institute for Health and Care Excellence (NICE) to ensure appropriate prescribing of all medicines on the lipids management pathway, alongside other factors such as lifestyle changes. The medicines that form the NICE and AAC recommended prescribing pathway for people with high cholesterol levels include bempedoic acid, ezetimibe, high intensity statins, inclisiran, PCSK9i, and statins.
A key ambition for the AHSN Network’s lipids programme is to ensure patients are prescribed the most appropriate medicine in a shared decision with their clinician.
Lipid management pathways for primary care and secondary care clinicians
Lipid management in England must improve to drive better CVD outcomes and, to address the clinical priority of improved lipid management, two pathways – one for acute cardiovascular disease in secondary care and one for primary care clinicians – have been developed to provide clear and simple guidance for clinicians on how optimal lipid management may be achieved and provide an additional resource to support patient management.
The first of these lipid optimisation pathways (lipid optimisation following an acute cardiovascular event) is now readily available as a guide to aid clinical practice. The second pathway (lipid optimisation pathway for secondary prevention in primary care) will be available before the end of 2022.
These pathways provide an additional resource which can be used to support patient management. They have been developed to support healthcare professionals in implementing NICE and other relevant evidence in lipid management in secondary prevention. These are not comprehensive clinical guidelines setting out all clinical scenarios, nor do they seek to set out the clinical evidence base for interventions which is covered in the relevant NICE Technology Appraisals.
During 2021, NICE recommended two novel therapies for patients with elevated cholesterol as part of the lipids management pathway: bempedoic acid and inclisiran. An overview of the collaboration between NHS England and Novartis Pharmaceuticals for the addition of inclisiran to the lipids management pathway is available on the AAC’s webpage.
The AHSN Network has a suite of implementation resources available to support the introduction of novel therapies into the lipids pathway. For further information and to get involved in our lipids national programme, please contact us using the contact form for the programme.